S-Medicon Kft.

Budapest IV 16 trials 4 recruiting

16 Registered trials

4 Currently recruiting

Organisation

S-Medicon Kft.

Location

Budapest IV, Hungary

Identifier

ORG-100044781

Address

Megyeri Ut 53, 1044, Hungary

Departments

#2102
#6504
n/a
NA
Neurologia
S-Medicon Egeszsegugyi Szolgaltato Kft.

Clinical trials at this site (16)

Search interface

A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has… Recruiting

2025-521636-10-00 Progressive Forms of Multiple Sclerosis (PMS) 4 2026-02-04
A study to investigate the safety and efficacy of MEDI0618 compared to placebo in adult participants with episodic migraine Recruiting

2024-512904-21-00 Migraine 4 2025-12-10
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Nervous system diseases 5 2024-05-20
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Partici… Ended

2025-521127-73-00 Relapsing forms of Multiple Sclerosis 5 2025-09-12
A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended

2024-512946-41-00 Menstrual Migraine 5 2025-03-05
Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended

2023-504359-29-01 Multiple sclerosis 5 2024-12-11
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Ended

2024-514343-29-00 multiple sclerosis 5 2024-11-19
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended

2022-501172-25-00 Chronic and Episodic Migraine 5 2024-01-17
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc… Ended

2022-502611-10-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-11-24
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended

2023-506467-34-00 Relapsing Multiple Sclerosis (MS) 5 2020-10-20
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended

2023-507906-15-00 Relapsing multiple sclerosis (RMS) 5 2019-01-30
A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended

2023-508821-28-00 Migraine 4 2024-08-14
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine Ended

2023-507096-21-00 Chronic or Episodic Migraine (Migraine without aura, mi 5 2021-08-16
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended

2024-514495-41-00 Primary Progressive Multiple Sclerosis 5 2020-11-04